Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Authors :: Anne Quinquenel
Rémi Letestu
Magali Le Garff-Tavernier
Fabien Subtil
Therese Aurran-Schleinitz
Kamel Laribi
Florence Cymbalista
Vincent Levy
Laurence Simon
Damien Roos-Weil
Véronique Leblond
Marie-Sarah Dilhuydy
Caroline Dartigeas
Cecile Tomowiak
Romain Guieze
Olivier Tournilhac
Emmanuelle Ferrant
Sophie de Guibert
Pierre Feugier
Fatiha Merabet
Stephane Lepretre
Philippe Carassou
Julie Gay
Bénédicte Hivert
Luc Mathieu Fornecker
Jehan Dupuis
Lysiane Molina
Bruno Villemagne
Guillaume Cartron
Bernard Drenou
Béatrice Mahé
Omar Benbrahim
Xavier Cahu
Christelle Portois
Loic Ysebaert
Florence Nguyen Khac
Valérie Rouille
Alain Delmer
Anne-Sophie Michallet
Source :: Blood. 140:7007-7009
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools